Boehringer Ingelheim, a market leader in animal health, announces the upcoming release of its Purevax® vaccine range for cats in 0.5 ml presentation. Thanks to its small volume, this new presentation of Purevax® makes cat vaccination convenient, allowing for a more gentle immunization experience for feline patients.
The Purevax® range protects cats from contracting the most important infectious feline diseases: feline herpesvirus (FHV) and feline calicivirus (FCV), feline panleukopenia virus (FPV), chlamydia felis, feline leukemia virus (FeLV) as well as rabies. Purevax® is the only fully adjuvant‑free feline vaccine range, combining optimal safety with proven efficacy. The Purevax® range also allows for flexibility by using the core components alone or in combination with non-core components, depending on the individual need of the cat.
“Purevax® 0.5 ml offers the same broad and flexible product range* as Purevax® 1.0 ml, with tailor-made solutions to suit every cat’s lifestyle. The new cat-friendly injection volume of 0.5 ml is a key benefit we are very excited about,” comments Dr Sandrine Lachérade, Global Marketing Director Pet Vaccines at Boehringer Ingelheim,” adding: “Veterinarians can count on Purevax® 0.5 ml to have the same efficacy as the Purevax® 1.0 ml range.”
Dr Jean-Philippe Tronel, Global Technical Director Pet Vaccines at Boehringer Ingelheim, gives further details: “Safety studies1 comparing the two presentations were carried out to obtain the EMA variation. The results of these studies, and especially the large-scale field trial in veterinary practices, suggested an improvement versus the already uncompromised safety of the 1.0 ml presentation1.”
The 0.5 ml vaccines contain the same amount and quality of antigens as the 1.0 ml products, so we have the same level of efficacy,” he elaborates. “Reducing the volume significantly provides an easier faster and smoother vaccination process.”
PUREVAX® also provides:
- Synergistic and broader protection with the most recent** and dual inactivated FCV vaccine strains2-4
- Rapid protection with one-week onset of immunity for core RCP components5
- Sustained protection up to three years for RCP and rabies components6-8
- Powerful immune response without adjuvant, thanks to innovative canarypox FeLV/rabies technology9-12
Boehringer Ingelheim expects to bring Purevax® 0.5 ml range to several markets worldwide in 2021.
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 10,000 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.
Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.
Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 countries. For more information visit: www.boehringer-ingelheim.com/animal-health/overview.